Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure
Raza M. Alvi(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Connor P. Mulligan(Harvard University), James L. Januzzi(Harvard University), Magid Awadalla(Massachusetts General Hospital), Anne M. Neilan(Harvard University), Adam Rokicki(Harvard University), Dahlia Banerji(Harvard University), Lili Zhang(Boston Children's Hospital), Maryam Afshar(Bronx-Lebanon Hospital Center), Markella V. Zanni(Harvard University), Noor Tariq(Yale New Haven Hospital), Malek Hassan(Massachusetts General Hospital)
Cited by 6
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study
|The American Journal of Cardiology|2005|1.2k
Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations
|European Journal of Heart Failure|2019|786